L-5103 Lepetit
Categorie
L-5103 Lepetit Les marques, L-5103 Lepetit Analogs
L-5103 Lepetit Les marques melange
L-5103 Lepetit Formule chimique
L-5103 Lepetit RX lien
L-5103 Lepetit FDA fiche
L-5103 Lepetit msds (fiche de securite des materiaux)
L-5103 Lepetit Synthese de reference
L-5103 Lepetit Poids moleculaire
L-5103 Lepetit Point de fusion
L-5103 Lepetit H2O Solubilite
L-5103 Lepetit Etat
L-5103 Lepetit LogP
L-5103 Lepetit Formes pharmaceutiques
L-5103 Lepetit Indication
L-5103 Lepetit Pharmacologie
L-5103 Lepetit Absorption
L-5103 Lepetit Toxicite
L-5103 Lepetit Information pour les patients
The patient should be told that rifampin may produce a reddish coloration of the urine, sweat, sputum, and tears, and the patient should be forewarned of this. Soft contact lenses may be permanently stained. The patients should be advised that the reliability of oral or other systemic hormonal contraceptives may be affected; consideration should be given to using alternative contraceptive measures. Patients should be instructed to take rifampin either 1 hour before or 2 hours after a meal with a full glass of water. Patients should be instructed to notify their physicians promptly if they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, and pain or swelling of the joints. Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses must be stressed.
